Glycoengineering of Interferon-β 1a improves its biophysical and pharmacokinetic properties

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Song, Kyoung ^a,b   Yoon, In Soo ^c   Kim, Nam Ah ^d   Kim, Dong Hwan ^a   Lee, Jongmin ^e   Lee, Hee Jung ^b   Lee, Saehyung ^a   Choi, Sunghyun ^b   Choi, Min Koo ^f   Kim, Ha Hyung ^g   Jeong, Seong Hoon ^d   Son, Woo Sung ^h   Kim, Dae Duk ^a   Shin, Young Kee ^a  

^a Seoul National University   (South Korea)

^b Abion Inc   (South Korea)

^c Mokpo National University   (South Korea)

^d Dongguk University   (South Korea)

^e PanGen Biotech Inc   (South Korea)

^f Dankook University   (South Korea)

^g Chung Ang University   (South Korea)

^h CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; MUTANT PROTEIN; R27T; UNCLASSIFIED DRUG; BETA INTERFERON; LIGAND; MONOSACCHARIDE; N ACETYLNEURAMINIC ACID;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLYCOENGINEERING; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; MULTIPLE SCLEROSIS; NONHUMAN; PLASMA CLEARANCE; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; RAT; SITE DIRECTED MUTAGENESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BINDING SITE; BIOPHYSICS; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; GLYCOSYLATION; METABOLISM; PROTEIN CONFORMATION; SOLUBILITY;

ANIMALS; BINDING SITES; BIOPHYSICAL PROCESSES; GLYCOSYLATION; HUMANS; INTERFERON-BETA; LIGANDS; MONOSACCHARIDES; MUTAGENESIS, SITE-DIRECTED; N-ACETYLNEURAMINIC ACID; PROTEIN CONFORMATION; PROTEIN STABILITY; RATS; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 84901414491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096967     Document Type: Article

References (43)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938-952.
2. Fitzner D, Simons M (2010) Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol 8: 305-315.
3. Amedei A, Prisco D, D'Elios MM (2012) Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci 13: 13438-13460.
4. de Seze J, Borgel F, Brudon F (2012) Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence 6: 263-273.
5. Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, et al. (2012) Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 5: 205-220.
6. Gasperini C, Ruggieri S (2011) Emerging oral drugs for relapsing-remitting multiple sclerosis. Expert Opin Emerg Drugs 16: 697-712.
7. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA (2011) Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther 5: 255-274.
8. Harris JM, Martin NE, Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539-551. (Pubitemid 32738660)
9. Watt GM, Lund J, Levens M, Kolli VS, Jefferis R, et al. (2003) Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function. Chem Biol 10: 807-814. (Pubitemid 37171899)
10. Katre NV (1993) The Conjugation of Proteins with Polyethylene-Glycol and Other Polymers - Altering Properties of Proteins to Enhance Their Therapeutic Potential. Advanced Drug Delivery Reviews 10: 91-114.
11. Kieseier BC, Calabresi PA (2012) PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis. CNS Drugs 26: 205-214.
12. Karpusas M, Whitty A, Runkel L, Hochman P (1998) The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 54: 1203-1216. (Pubitemid 28529112)
13. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, et al. (1998) Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15: 641-649. (Pubitemid 28214960)
14. Derynck R, Remaut E, Saman E, Stanssens P, De Clercq E, et al. (1980) Expression of human fibroblast interferon gene in Escherichia coli. Nature 287: 193-197. (Pubitemid 10019764)
15. Mark DF, Lu SD, Creasey AA, Yamamoto R, Lin LS (1984) Site-specific mutagenesis of the human fibroblast interferon gene. Proc Natl Acad Sci U S A 81: 5662-5666. (Pubitemid 14023825)
16. Kagawa Y, Takasaki S, Utsumi J, Hosoi K, Shimizu H, et al. (1988) Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J Biol Chem 263: 17508-17515. (Pubitemid 19029332)
17. Sola RJ, Griebenow K (2009) Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98: 1223-1245.
18. Wang W (2005) Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289: 1-30.
19. Rodriguez J, Spearman M, Tharmalingam T, Sunley K, Lodewyks C, et al. (2010) High productivity of human recombinant beta-interferon from a lowtemperature perfusion culture. J Biotechnol 150: 509-518.
20. Rodriguez J, Spearman M, Huzel N, Butler M (2005) Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions. Biotechnol Prog 21: 22-30. (Pubitemid 40218468)
21. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, et al. (1997) The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci U S A 94: 11813-11818.
22. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
23. Sanner MF, Olson AJ, Spehner JC (1996) Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38: 305-320.
24. Kirschner KN, Woods RJ (2001) Quantum mechanical study of the nonbonded forces in water-methanol complexes. J Phys Chem A 105: 4150-4155.
25. Basma M, Sundara S, Calgan D, Vernali T, Woods RJ (2001) Solvated ensemble averaging in the calculation of partial atomic charges. J Comput Chem 22: 1125-1137. (Pubitemid 32662792)
26. Kirschner KN, Woods RJ (2001) Solvent interactions determine carbohydrate conformation. Proc Natl Acad Sci U S A 98: 10541-10545. (Pubitemid 32884115)
27. Quadt-Akabayov SR, Chill JH, Levy R, Kessler N, Anglister J (2006) Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex. Protein Sci 15: 2656-2668. (Pubitemid 44771702)
28. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725. (Pubitemid 44583220)
29. Yoon I, Han S, Choi YH, Kang HE, Cho HJ, et al. (2012) Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats. Xenobiotica 42: 1110-1119.
30. Kim JE, Cho HJ, Kim JS, Shim CK, Chung SJ, et al. (2013) The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. Xenobiotica 43: 579-591.
31. Yang CH, Wu PC, Huang YB, Tsai YH (2004) A new approach for determining the stability of recombinant human epidermal growth factor by thermal Fourier transform infrared (FTIR) microspectroscopy. J Biomol Struct Dyn 22: 101-110. (Pubitemid 39095287)
32. Dong A, Prestrelski SJ, Allison SD, Carpenter JF (1995) Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J Pharm Sci 84: 415-424.
33. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR (2005) Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. J Pharm Sci 94: 1893-1911. (Pubitemid 41551475)
34. Hubbard SJT (1993) NACCESS. Computer Program, Department of Biochemistry and Molecular Biology, University College London.
35. Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, et al. (1998) Differences in activity between alpha and beta type I interferons explored by mutational analysis. J Biol Chem 273: 8003-8008. (Pubitemid 28168850)
36. Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, et al. (2000) Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. Biochemistry 39: 2538-2551. (Pubitemid 30148906)
37. Shental-Bechor D, Levy Y (2008) Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci U S A 105: 8256- 8261.
38. Knight P (1989) The Carbohydrate Frontier. Bio-Technology 7: 35-&.
39. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, et al. (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297: 1059-1066. (Pubitemid 32472504)
40. Wanic-Kossowska M, Tykarski A, Kobelski M, Czekalski S (2006) [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period]. Pol Arch Med Wewn 116: 663-670.
41. Fang YW, Chang CH (2009) Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients. Perit Dial Int 29: 199-203.
42. Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24: 1241-1252. (Pubitemid 44564769)
43. Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, et al. (1992) Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31: 9871-9876.